| BioLife Solutions to Participate in Upcoming Investor Conferences in May and June 2025 |
BOTHELL, Wash. , May 14, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the company will be participating in the following investor conferences: 22nd Annual Craig-Hallum Institutional Investor Conference May 28, 2025 Minneapolis, MN at the Renaissance Hotel Benchmark 2025 Healthcare House Call Virtual Conference May 29, 2025 Virtual Jefferies Global Life Sciences Conference June 3 – 5, 2025 New York, NY at the Marriott Marquis Wolfe Research Small & Mid-Cap Conference June 5, 2025 New York, NY at Wolfe Headquarters Northland Growth Conference 2025 June 25, 2025 Virtual About BioLife Solutions BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. |
prnewswire.com |
2025-05-14 12:03:00 |
Czytaj oryginał (ang.) |
| Can BioLife Solutions (BLFS) Climb 30.68% to Reach the Level Wall Street Analysts Expect? |
The consensus price target hints at a 30.7% upside potential for BioLife Solutions (BLFS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-05-13 15:01:18 |
Czytaj oryginał (ang.) |
| BioLife Solutions, Inc. (BLFS) Q1 2025 Earnings Call Transcript |
BioLife Solutions, Inc. (NASDAQ:BLFS ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Troy Wichterman - Chief Financial Officer Roderick de Greef - Chairman and Chief Executive Officer Conference Call Participants Matthew Stanton - Jefferies Paul Knight - KeyBanc Chad Wiatrowski - TD Cowen Thomas Flaten - Lake Street Matthew Hewitt - Craig-Hallum Capital Group Carl Byrnes - Northland Capital Markets Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and thank you for standing by. |
seekingalpha.com |
2025-05-09 02:59:14 |
Czytaj oryginał (ang.) |
| BioLife Solutions, Inc. (BLFS) Q1 Earnings and Revenues Beat Estimates |
BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.19 per share a year ago. |
zacks.com |
2025-05-08 22:25:34 |
Czytaj oryginał (ang.) |
| BioLife Solutions Updates Earnings Call Information |
BOTHELL, Wash. , May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, is announcing corrected call-in numbers for their Earnings Call this afternoon at 4:30pm ET. |
prnewswire.com |
2025-05-08 20:32:00 |
Czytaj oryginał (ang.) |
| BioLife Solutions Reports First Quarter 2025 Financial Results |
Cell Processing revenue of $21.6 million, up 33% over Q1 2024 GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66% GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million or 24% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash. |
prnewswire.com |
2025-05-08 20:03:00 |
Czytaj oryginał (ang.) |
| Stock Picks From Seeking Alpha's April 2025 New Analysts |
In April, Seeking Alpha welcomed 20 new analysts. This article introduces them and showcases some of their top picks. Top picks include Palantir, Arch Capital Group, and Utah Medical Products, emphasizing an under-recognized growth driver, discounted valuation, and a substantial margin of safety. Analysts also highlighted Sell recommendations on Estée Lauder and Intuitive Surgical, citing deteriorating consumer sentiment and little price upside. |
seekingalpha.com |
2025-05-06 12:00:00 |
Czytaj oryginał (ang.) |
| BioLife Solutions to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025 |
BOTHELL, Wash. , April 30, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's first quarter 2025 financial results will be released after market close on Thursday, May 8, 2025. |
prnewswire.com |
2025-04-30 12:03:00 |
Czytaj oryginał (ang.) |
| BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company |
Strategic acquisition enhances biopreservation media portfolio with novel Ice Recrystallization Inhibitor technology Marks the second acquisition from Bioproduction Innovation Accelerator program BOTHELL, Wash. , April 7, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the acquisition of privately-held PanTHERA CryoSolutions, Inc., ("PanTHERA"), a developer of novel cryopreservation solutions based on proprietary Ice Recrystallization Inhibitor ("IRI") technology. |
prnewswire.com |
2025-04-07 12:03:00 |
Czytaj oryginał (ang.) |
| BioLife Solutions: A Steady Stock Lined Up For Success In A Booming Industry |
BioLife Solutions, an established biotech firm, is poised to benefit from the booming cell and gene therapy sector, projected to grow significantly by 2030. Despite recent negative EPS, BioLife has consistently exceeded earnings expectations, indicating strong future potential and investor confidence. BioLife's unique focus on cell preservation and storage positions it advantageously within the CGT sector, with expected revenue growth heavily outpacing peers. |
seekingalpha.com |
2025-04-06 08:43:43 |
Czytaj oryginał (ang.) |
| 5 Low-Leverage Stocks to Buy Amid Trump's Tariff Woes |
The majority of U.S. stock indices ended barely in the green on March 21, 2025, overcoming their recent losing streaks since investors remain wary about the long-term economic impacts of President Trump's enhanced import tariffs. The latest uptick in the major stock indices was mostly because the Federal Reserve kept its projection for interest rate cuts broadly unchanged, indicating economic stability for the time being. |
zacks.com |
2025-03-24 10:30:21 |
Czytaj oryginał (ang.) |
| BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair |
BOTHELL, Wash. , March 18, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Cathy Coste to its board of directors, increasing board membership to seven. |
prnewswire.com |
2025-03-18 10:30:00 |
Czytaj oryginał (ang.) |
| 5 Low-Leverage Stocks to Buy Amid Volatile Market Sentiment |
The crux of safe investment lies in choosing a company that is not burdened with debt. You may buy BLFS, BHLB, NVDA, GBX and EZPW. |
zacks.com |
2025-03-10 13:00:31 |
Czytaj oryginał (ang.) |
| BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates |
BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.30 per share a year ago. |
zacks.com |
2025-03-03 11:10:28 |
Czytaj oryginał (ang.) |
| BioLife Solutions Reports Fourth Quarter and Full Year 2024 Financial Results |
Cell Processing revenue up 7% sequentially to $20.3 million in the fourth quarter; 2024 Cell Processing revenue up 12% over prior year to $73.5 million GAAP gross margin of 60% and non-GAAP adjusted gross margin of 63% for the fourth quarter GAAP net loss from continuing operations of $2.0 million and non-GAAP adjusted EBITDA of $4.0 million, or 18% of total revenue for the fourth quarter Expects 2025 Cell Processing revenue of $86.5 to $89.0 million, up 18% to 21% over 2024 and total revenue of $95.5 to $99.0 million, up 16% to 20% over 2024 Conference call begins at 8:00 a.m. Eastern time today BOTHELL, Wash. |
prnewswire.com |
2025-03-03 09:00:00 |
Czytaj oryginał (ang.) |
| BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025 |
BOTHELL, Wash. , Feb. 20, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2024 fourth quarter and full year financial results will be released on March 3, 2025 pre-market. |
prnewswire.com |
2025-02-20 18:03:00 |
Czytaj oryginał (ang.) |
| Recent Price Trend in BioLife Solutions (BLFS) is Your Friend, Here's Why |
BioLife Solutions (BLFS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. |
zacks.com |
2025-02-12 11:51:22 |
Czytaj oryginał (ang.) |
| BioLife Solutions, Inc. (BLFS) Hit a 52 Week High, Can the Run Continue? |
BioLife Solutions (BLFS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
zacks.com |
2025-01-29 12:16:27 |
Czytaj oryginał (ang.) |
| Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year? |
Here is how BioLife Solutions, Inc. (BLFS) and Ginkgo Bioworks Holdings, Inc. (DNA) have performed compared to their sector so far this year. |
zacks.com |
2025-01-24 12:41:35 |
Czytaj oryginał (ang.) |
| BioLife Solutions (BLFS) Is a Great Choice for 'Trend' Investors, Here's Why |
If you are looking for stocks that are well positioned to maintain their recent uptrend, BioLife Solutions (BLFS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
zacks.com |
2025-01-22 11:50:26 |
Czytaj oryginał (ang.) |
| BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2024 Unaudited Revenue from Continuing Operations |
Fourth quarter Cell Processing revenue increased 7% sequentially to $20.3 million Unaudited revenue for FY2024 from Cell Processing of $73.5 million, exceeded the high end of previously raised guidance BOTHELL, Wash. , Jan. 13, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced 2024 fourth quarter and full year preliminary unaudited revenue from continuing operations. |
prnewswire.com |
2025-01-13 10:30:00 |
Czytaj oryginał (ang.) |
| BioLife Solutions price target raised to $31 from $28 at Northland |
Northland raised the firm's price target on BioLife Solutions to $31 from $28 and keeps an Outperform rating on the shares. With the divestiture of its freezer businesses and the recent sale of SciSafe biostorage, the firm believes BioLife is positioned to "emerge as a leading consolidator in the sector" as the company refocuses on its core expertise in biopreservation media and cell processing products and services for cell and gene therapies, the analyst tells investors. |
https://thefly.com |
2025-01-08 10:43:46 |
Czytaj oryginał (ang.) |
| BioLife Solutions Appoints Tony J. Hunt to its Board of Directors |
BOTHELL, Wash. , Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. |
prnewswire.com |
2024-12-16 10:11:00 |
Czytaj oryginał (ang.) |
| BioLife Solutions Announces $6.1 million Sale of its Custom Biogenic Systems Freezer Subsidiary |
Completes the Company's strategic move away from capital equipment businesses BOTHELL, Wash. , Nov. 14, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the sale of its final wholly owned freezer subsidiary, Arctic Solutions, Inc. ("Custom Biogenic Systems" or "CBS"), for $6.1 million in cash. |
prnewswire.com |
2024-11-14 18:05:00 |
Czytaj oryginał (ang.) |
| BioLife Solutions, Inc. (BLFS) Q3 2024 Earnings Call Transcript |
BioLife Solutions, Inc. (NASDAQ:BLFS ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Troy Wichterman - Chief Financial Officer Rod de Greef - Chairman and Chief Executive Officer Garrie Richardson - Chief Revenue Officer Conference Call Participants Matt Stanton - Jefferies Brendan Smith - TD Cowen Anna Snopkowski - KeyBanc Matt Hewitt - Craig-Hallum Capital Group LLC Thomas Flaten - Lake Street Capital Markets Jade Montgomery - H.C. Wainwright & Co., LLC Operator Good afternoon, ladies and gentlemen, and thank you for standing by. |
seekingalpha.com |
2024-11-12 22:41:00 |
Czytaj oryginał (ang.) |
| BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Tops Revenue Estimates |
BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.67 per share a year ago. |
zacks.com |
2024-11-12 20:51:21 |
Czytaj oryginał (ang.) |
| BioLife Solutions Reports Third Quarter 2024 Financial Results |
Cell Processing revenue grew 6% sequentially to $19.0 million; 43% increase compared to 2023 GAAP gross margin of 51% and non-GAAP adjusted gross margin of 54% GAAP net loss from continuing operations of $1.7 million and non-GAAP adjusted EBITDA of $6.1 million or 20% Increasing Cell Processing revenue guidance by $2 million to $72.0 to $73.0 million; total 2024 revenue guidance of $98.0 million to $100.0 million reflecting impact of SciSafe divestiture Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash. |
prnewswire.com |
2024-11-12 18:05:00 |
Czytaj oryginał (ang.) |
| BioLife Solutions Announces $73 Million Sale of its SciSafe Biostorage Subsidiary |
Strategic divestiture heightens focus on proprietary, higher-margin cell processing products All-cash transaction fortifies balance sheet BOTHELL, Wash. , Nov. 12, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market, announces the sale of its wholly owned biostorage subsidiary SciSafe Holdings, Inc. ("SciSafe") for $73 million in cash. |
prnewswire.com |
2024-11-12 10:05:00 |
Czytaj oryginał (ang.) |
| BioLife Solutions to Report Third Quarter 2024 Financial Results and Business Update on November 12, 2024 |
BOTHELL, Wash. , Oct. 31, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter 2024 financial results will be released after market close on Tuesday, November 12, 2024. |
prnewswire.com |
2024-10-31 18:03:00 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging BioLife Solutions (BLFS) This Year? |
Here is how BioLife Solutions, Inc. (BLFS) and Eli Lilly (LLY) have performed compared to their sector so far this year. |
zacks.com |
2024-10-21 14:46:36 |
Czytaj oryginał (ang.) |
| Here's Why Momentum in BioLife Solutions (BLFS) Should Keep going |
BioLife Solutions (BLFS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
zacks.com |
2024-10-07 13:51:14 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging BioLife Solutions (BLFS) This Year? |
Here is how BioLife Solutions, Inc. (BLFS) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year. |
zacks.com |
2024-09-17 14:46:17 |
Czytaj oryginał (ang.) |
| BioLife Is Cleaning Ship |
BioLife was overextended on acquisitions, leading to margin compression and dilution of shareholder capital. The company has divested from non-core businesses, focusing on preservation media where it is a market leader. Improved financial results include gross margin expansion, lower OpEx, and increased revenue guidance, driven by growth in the Cell Processing business. |
seekingalpha.com |
2024-08-20 19:51:14 |
Czytaj oryginał (ang.) |
| BioLife Solutions, Inc. (BLFS) Q2 2024 Earnings Call Transcript |
BioLife Solutions, Inc. (NASDAQ:BLFS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Troy Wichterman – Chief Financial Officer Rod de Greef – Chairman and Chief Executive Officer Garrie Richardson – Chief Revenue Officer Conference Call Participants Jacob Johnson – Stephens Anna Snopkowski – KeyBanc Matt Stanton – Jefferies Steven Mah – TD Cowen Thomas Flaten – Lake Street Capital Markets Operator Good afternoon, and welcome to the BioLife Solutions Q2 2024 Shareholder and Analyst Conference Call. [Operator Instructions] Please note, this event is being recorded. |
seekingalpha.com |
2024-08-09 23:50:26 |
Czytaj oryginał (ang.) |
| BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates |
BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.23 per share a year ago. |
zacks.com |
2024-08-08 22:46:06 |
Czytaj oryginał (ang.) |
| BioLife Solutions Reports Second Quarter 2024 Financial Results |
Cell Processing revenue increased 11% sequentially to $18.0 million GAAP gross margin of 51% and non-GAAP adjusted gross margin of 52% GAAP net loss from continuing operations of $7.1 million and non-GAAP adjusted EBITDA of $4.8 million or 17% Raising full-year 2024 total revenue guidance to $99.0 million to $101.0 million; Cell Processing revenue guidance increased to $70.0 million to $71.0 million Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash. |
prnewswire.com |
2024-08-08 20:03:00 |
Czytaj oryginał (ang.) |
| BioLife Solutions to Report Second Quarter 2024 Financial Results and Business Update on August 8, 2024 |
BOTHELL, Wash. , July 25, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. |
prnewswire.com |
2024-07-25 20:03:00 |
Czytaj oryginał (ang.) |
| What Makes BioLife Solutions (BLFS) a Good Fit for 'Trend Investing' |
BioLife Solutions (BLFS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
zacks.com |
2024-07-12 13:52:36 |
Czytaj oryginał (ang.) |
| BioLife (BLFS) Progresses in Cell & Gene Therapy With CryoCase |
BioLife's (BLFS) latest product, CryoCase, is compatible with various downstream processing systems, including its own Signata CT-5. |
zacks.com |
2024-05-31 16:21:08 |
Czytaj oryginał (ang.) |
| BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouver |
New container developed for the needs of cell and gene therapy (CGT) primary packaging to replace cryopreservation bags with a fracture resistant, rigid construction built for both manual use and closed-system automation. BOTHELL, Wash. |
prnewswire.com |
2024-05-29 12:04:00 |
Czytaj oryginał (ang.) |
| BioLife Solutions, Inc. (BLFS) Q1 2024 Earnings Call Transcript |
Start Time: 16:30 January 1, 0000 5:02 PM ET BioLife Solutions, Inc. (NASDAQ:BLFS ) Q1 2024 Earnings Conference Call May 09, 2024, 16:30 PM ET Company Participants Rod de Greef - Chairman and CEO Troy Wichterman - CFO Garrie Richardson - Chief Revenue Officer Conference Call Participants Paul Knight - KeyBanc Hannah Hefley - Stephen Inc. Matthew Stanton - Jefferies Matt Hewitt - Craig-Hallum Capital Group Thomas Flaten - Lake Street Capital Operator Welcome to the BioLife Solutions First Quarter 2024 Financial Results and Business Update. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-05-10 00:36:03 |
Czytaj oryginał (ang.) |
| BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Tops Revenue Estimates |
BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.32 per share a year ago. |
zacks.com |
2024-05-09 23:05:14 |
Czytaj oryginał (ang.) |